Engineering Customized Nanovaccines for Enhanced Cancer Immunotherapy

Overview

Journal Bioact Mater

Specialty Biomedical Engineering

Date 2024 Mar 18

PMID 38496036

Authors

Jinyu Guo

Changhua Liu

Zhaoyang Qi

Ting Qiu

Jin Zhang

Huanghao Yang

Affiliations

Soon will be listed here.

Abstract

Nanovaccines have gathered significant attention for their potential to elicit tumor-specific immunological responses. Despite notable progress in tumor immunotherapy, nanovaccines still encounter considerable challenges such as low delivery efficiency, limited targeting ability, and suboptimal efficacy. With an aim of addressing these issues, engineering customized nanovaccines through modification or functionalization has emerged as a promising approach. These tailored nanovaccines not only enhance antigen presentation, but also effectively modulate immunosuppression within the tumor microenvironment. Specifically, they are distinguished by their diverse sizes, shapes, charges, structures, and unique physicochemical properties, along with targeting ligands. These features of nanovaccines facilitate lymph node accumulation and activation/regulation of immune cells. This overview of bespoke nanovaccines underscores their potential in both prophylactic and therapeutic applications, offering insights into their future development and role in cancer immunotherapy.

Citing Articles

Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.

Wang M, Yu F, Zhang Y Mol Cancer. 2025; 24(1):26.

PMID: 39827147 PMC: 11748575. DOI: 10.1186/s12943-024-02214-5.

Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management - a comprehensive review.

Kumar N, Mangla M Cancer Chemother Pharmacol. 2025; 95(1):18.

PMID: 39754614 DOI: 10.1007/s00280-024-04747-4.

Emerging Cationic Nanovaccines.

Carmona-Ribeiro A, Perez-Betancourt Y Pharmaceutics. 2024; 16(11).

PMID: 39598488 PMC: 11597065. DOI: 10.3390/pharmaceutics16111362.

Advancements in Engineering Planar Model Cell Membranes: Current Techniques, Applications, and Future Perspectives.

Coronado S, Herrera J, Pino M, Martin S, Ballesteros-Rueda L, Cea P Nanomaterials (Basel). 2024; 14(18).

PMID: 39330645 PMC: 11434481. DOI: 10.3390/nano14181489.

References

Huang J, Leng X, Jiang T, Xu L, Zheng J, Fang M . Oxygen-carrying nanoplatform to reprogram tumor immunosuppressive microenvironment and enhance photothermal-immunotherapy. Mater Today Bio. 2023; 19:100555. PMC: 9922928. DOI: 10.1016/j.mtbio.2023.100555. View

Yang L, Wang T, Zhang D, Huang X, Dong Y, Gao W . Black Phosphorus Nanosheets Assist Nanoerythrosomes for Efficient mRNA Vaccine Delivery and Immune Activation. Adv Healthc Mater. 2023; 12(26):e2300935. DOI: 10.1002/adhm.202300935. View

John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw C . Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018; 36(12):1689-1699. DOI: 10.1016/j.vaccine.2018.01.029. View

Su T, Liu X, Lin S, Cheng F, Zhu G . Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. Bioact Mater. 2023; 26:169-180. PMC: 9982230. DOI: 10.1016/j.bioactmat.2023.02.016. View

Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R . Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy. Nano Lett. 2021; 21(5):2224-2231. DOI: 10.1021/acs.nanolett.0c05039. View

Hu X, Wu T, Qin X, Qi Y, Qiao Q, Yang C . Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy. Adv Healthc Mater. 2018; 8(1):e1800837. DOI: 10.1002/adhm.201800837. View

Wang M, Yin B, Wang H, Wang R . Current advances in T-cell-based cancer immunotherapy. Immunotherapy. 2014; 6(12):1265-78. PMC: 4372895. DOI: 10.2217/imt.14.86. View

Costa Da Silva M, Breckwoldt M, Vinchi F, Correia M, Stojanovic A, Thielmann C . Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. Front Immunol. 2017; 8:1479. PMC: 5682327. DOI: 10.3389/fimmu.2017.01479. View

Liu S, Jiang Q, Zhao X, Zhao R, Wang Y, Wang Y . A DNA nanodevice-based vaccine for cancer immunotherapy. Nat Mater. 2020; 20(3):421-430. DOI: 10.1038/s41563-020-0793-6. View

10.

Chen S, Barrientos J, Ferrer G, King-Richards M, Chen Y, Ravichandran P . Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model. Clin Cancer Res. 2023; 29(10):1984-1995. PMC: 10192081. DOI: 10.1158/1078-0432.CCR-22-2386. View

11.

Su R, Chong G, Dong H, Gu J, Zang J, He R . Nanovaccine biomineralization for cancer immunotherapy: a NADPH oxidase-inspired strategy for improving antigen cross-presentation via lipid peroxidation. Biomaterials. 2021; 277:121089. DOI: 10.1016/j.biomaterials.2021.121089. View

12.

Carson C, Becker K, Garland K, Pagendarm H, Stone P, Arora K . A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA. J Control Release. 2022; 345:354-370. PMC: 9133199. DOI: 10.1016/j.jconrel.2022.03.020. View

13.

Ramesh A, Brouillard A, Kumar S, Nandi D, Kulkarni A . Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy. Biomaterials. 2019; 227:119559. PMC: 7238715. DOI: 10.1016/j.biomaterials.2019.119559. View

14.

Chen S, Xu X, Zhang Y, Ye L, Zhang L, Li L . Nanovaccine Based on a Biepitope Antigen to Potentiate the Immunogenicity of a Neoantigen. ACS Macro Lett. 2023; 12(2):281-287. DOI: 10.1021/acsmacrolett.2c00742. View

15.

Mant A, Chinnery F, Elliott T, Williams A . The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen. Immunology. 2012; 136(2):163-75. PMC: 3403259. DOI: 10.1111/j.1365-2567.2012.03558.x. View

16.

Li F, Feng X, Huang J, Zhang M, Liu W, Wang X . Periodic Mesoporous Organosilica as a Nanoadjuvant for Subunit Vaccines Elicits Potent Antigen-Specific Germinal Center Responses by Activating Naive B Cells. ACS Nano. 2023; 17(16):15424-15440. DOI: 10.1021/acsnano.3c00991. View

17.

Vinardell M, Mitjans M . Antitumor Activities of Metal Oxide Nanoparticles. Nanomaterials (Basel). 2017; 5(2):1004-1021. PMC: 5312892. DOI: 10.3390/nano5021004. View

18.

Wang N, Chen M, Wang T . Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization. J Control Release. 2019; 303:130-150. PMC: 7111479. DOI: 10.1016/j.jconrel.2019.04.025. View

19.

Diao L, Liu M . Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell. Adv Sci (Weinh). 2023; 10(22):e2300121. PMC: 10401146. DOI: 10.1002/advs.202300121. View

20.

Blanco E, Kessinger C, Sumer B, Gao J . Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood). 2008; 234(2):123-31. PMC: 2864888. DOI: 10.3181/0808-MR-250. View